3,4-dihydro-5-methyl-1(2h)-isoquinolinone has been researched along with methoxyamine in 1 studies
Studies (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Trials (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Recent Studies (post-2010) (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Studies (methoxyamine) | Trials (methoxyamine) | Recent Studies (post-2010) (methoxyamine) |
---|---|---|---|---|---|
16 | 0 | 2 | 152 | 1 | 43 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chatterjee, S; Gerson, SL; Liu, L; Taverna, P; Whitacre, CM | 1 |
1 other study(ies) available for 3,4-dihydro-5-methyl-1(2h)-isoquinolinone and methoxyamine
Article | Year |
---|---|
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Colonic Neoplasms; Dacarbazine; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 1999 |